7113 results
Cited 4 times since 2024 (4 per year)
source: EuropePMC
Atherosclerosis,
Volume 398, 7 1 2024, Pages 118595
Arterial inflammation on [<sup>18</sup>F]FDG PET/CT in melanoma patients treated with and without immune checkpoint inhibitors: CHECK-FLAME I.
Polomski EAS, Kapiteijn EW, Heemelaar JC, van der Kolk AV, Kalisvaart TM, van de Burgt A, Dibbets-Schneider P, van Velden FHP, Seijkens TTP, Stöger JL, Jukema JW, de Geus-Oei LF, Antoni ML
Background and aims: Immune checkpoint inhibitors (ICIs) revolutionized cancer treatment. However, ICIs may increase the immune response to non-tumor cells, possibly resulting in increased arterial inflammation, raising the risk of atherosclerotic events. Nevertheless, malignancies may induce a pro-inflammatory state and the association between ICIs and arterial inflammation remains to be clarified. This study aims to assess differences in increase in arterial inflammation between patients with...
Abstract
Heart rhythm,
Volume 22, Issue 6, 6 1 2024, Pages 1384-1393
Lesion delivery and scar formation in catheter ablation for atrial fibrillation: The DECAAF II trial.
Akoum N, Mekhael M, Bisbal F, Wazni O, McGann C, Lee H, Bardsley T, Greene T, Dean JM, Dagher L, Kholmovski E, Mansour M, Marchlinski F, Wilber D, Hindricks G, Mahnkopf C, Wells D, Jaïs P, Sanders P, Brachmann J, Bax JJ, Morrison-de Boer L, Deneke T, Calkins H, Sohns C, Marrouche N, DECAAF II investigators
Background: The Efficacy of Delayed Enhancement MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation of Atrial Fibrillation randomized trial showed no difference in atrial fibrillation (AF) recurrence with additional delayed enhancement magnetic resonance imaging (DE-MRI) fibrosis-targeted ablation to pulmonary vein isolation (PVI) in persistent AF. Objective: We evaluated the effect of lesion delivery on ablation-induced scarring and AF recurrence. Methods: Lesions delivered, targetin...
Abstract
Frontiers in neuroscience,
Volume 18, 6 1 2024, Pages 1450640
Memory-efficient neurons and synapses for spike-timing-dependent-plasticity in large-scale spiking networks.
Urbizagastegui P, van Schaik A, Wang R
This paper addresses the challenges posed by frequent memory access during simulations of large-scale spiking neural networks involving synaptic plasticity. We focus on the memory accesses performed during a common synaptic plasticity rule since this can be a significant factor limiting the efficiency of the simulations. We propose neuron models that are represented by only three state variables, which are engineered to enforce the appropriate neuronal dynamics. Additionally, memory retrieval is...
Abstract
Cited 1 times since 2024 (1 per year)
source: EuropePMC
Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists,
5 1 2024, Pages 15266028241274568
Maximal Systolic Acceleration and Near-Infrared Fluorescence Imaging With Indocyanine Green as Predictors for Successful Lower Extremity Revascularization.
Kruiswijk MW, Willems SA, Koning S, Tange FP, J W M Brouwers J, Peul RC, van Schaik J, Schepers A, Hamming J, van der Bogt KEA, van Rijswijk CSP, Vahrmeijer AL, van den Hoven P, van der Vorst JR
Background: Patients with lower extremity arterial disease (LEAD) frequently require revascularization procedures. Currently used diagnostic methods are insufficient in predicting successful outcomes and focus on macrovascular rather than microvascular state. Several promising modalities to increase diagnostic accuracy are emerging, including maximal systolic acceleration (ACCmax), measured by duplex ultrasound (DUS). For the assessment of tissue perfusion, near-infrared fluorescence (NIR) imagi...
Abstract
The Pediatric infectious disease journal,
Volume 44, Issue 1, 4 1 2024, Pages 83-89
Pediatric Varicella-related Hospitalization in Turkey Between 2008 and 2018: Impact of Universal Single Dose Varicella Vaccine (VARICOMP Study).
Dinleyici EC, Kurugol Z, Devrim I, Bayram N, Dalgic N, Yasa O, Tezer H, Ozdemir H, Ciftci E, Tapisiz A, Celebi S, Hacimustafaoglu M, Yilmaz D, Hatipoglu N, Kara A, VARICOMP Study Group
Background: A single-dose varicella vaccine at 12 months of age was introduced to the National Immunization Program in February 2013 in Turkey. This study aimed to evaluate varicella-related hospitalization in children and the impact of a single-dose live attenuated varicella vaccine over the first 5.5 years of introducing a universal varicella vaccination. Methods: We analyzed data collected from the medical records of children
Abstract
Cited 1 times since 2024 (1 per year)
source: EuropePMC
American heart journal,
Volume 278, 2 1 2024, Pages 61-71
Low-dose colchicine for the prevention of cardiovascular events after percutaneous coronary intervention: Rationale and design of the COL BE PCI trial.
De Cock E, Kautbally S, Timmermans F, Bogaerts K, Hanet C, Desmet W, Gurné O, Vranckx P, Hiltrop N, Dujardin K, Vanduynhoven P, Vermeersch P, Pirlet C, Hermans K, Van Reet B, Ferdinande B, Aminian A, Dewilde W, Guédès A, Simon F, De Roeck F, De Vroey F, Jukema JW, Sinnaeve P, Buysschaert I
Introduction: Patients with coronary artery disease (CAD) remain vulnerable to future major atherosclerotic events after revascularization, despite effective secondary prevention strategies. Inflammation plays a central role in the pathogenesis of CAD and recurrent events. To date, there is no specific anti-inflammatory medicine available with proven effective, cost-efficient, and favorable benefit-risk profile, except for colchicine. Initial studies with colchicine have sparked major interest i...
Abstract
Cited 8 times since 2024 (7.8 per year)
source: EuropePMC
Journal of the American College of Cardiology,
Volume 84, Issue 13, 1 1 2024, Pages 1178-1189
Temporal Trends in Takotsubo Syndrome: Results From the International Takotsubo Registry.
Schweiger V, Cammann VL, Crisci G, Gilhofer T, Schlenker R, Niederseer D, Chen S, Ebrahimi R, Wenzl F, Würdinger M, Citro R, Vecchione C, Gili S, Neuhaus M, Franke J, Meder B, Jaguszewski M, Noutsias M, Knorr M, Jansen T, D'Ascenzo F, Dichtl W, von Lewinski D, Burgdorf C, Kherad B, Tschöpe C, Sarcon A, Shinbane J, Rajan L, Michels G, Pfister R, Cuneo A, Jacobshagen C, Karakas M, Koenig W, Pott A, Meyer P, Roffi M, Banning A, Wolfrum M, Cuculi F, Kobza R, Fischer TA, Vasankari T, Airaksinen KEJ, Napp LC, Dworakowski R, MacCarthy P, Kaiser C, Osswald S, Galiuto L, Chan C, Bridgman P, Beug D, Delmas C, Lairez O, Gilyarova E, Shilova A, Gilyarov M, El-Battrawy I, Akin I, Poledniková K, Toušek P, Winchester DE, Massoomi M, Galuszka J, Ukena C, Poglajen G, Carrilho-Ferreira P, Hauck C, Paolini C, Bilato C, Kobayashi Y, Kato K, Ishibashi I, Himi T, Din J, Al-Shammari A, Prasad A, Rihal CS, Liu K, Schulze PC, Bianco M, Jörg L, Rickli H, Pestana G, Nguyen TH, Böhm M, Maier LS, Pinto FJ, Widimský P, Felix SB, Braun-Dul
Background: The perception of takotsubo syndrome (TTS) has evolved significantly over the years, primarily driven by increased recognition of acute complications and mortality. Objectives: This study aimed to explore temporal trends in demographic patterns, risk factors, clinical presentations, and outcomes in patients with TTS. Methods: Patients diagnosed with TTS between 2004 and 2021 were enrolled from the InterTAK (International Takotsubo) registry. To assess temporal trends, patients were d...
Abstract
Cited 6 times since 2024 (5.9 per year)
source: EuropePMC
Journal of the American College of Cardiology,
Volume 84, Issue 11, 1 1 2024, Pages 994-1006
Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome.
Zahger D, Schwartz GG, Du W, Szarek M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Jukema JW, Kiss RG, Harrington RA, Moriarty PM, Scemama M, Manvelian G, Pordy R, White HD, Zeiher AM, Fazio S, Geba GP, Steg PG, ODYSSEY OUTCOMES Investigators
Background: It is unknown whether clinical benefit of proprotein convertase subtilisin/kexin type 9 inhibitors is associated with baseline or on-treatment triglyceride concentrations. Objectives: This study sought to examine relations between triglyceride levels and the effect of alirocumab vs placebo on cardiovascular outcomes using prespecified and post hoc analyses of the ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab)...
Abstract
Cited 2 times since 2024 (2 per year)
source: EuropePMC
Neural computation,
Volume 36, Issue 10, 1 1 2024, Pages 1939-2029
Electrical Signaling Beyond Neurons.
Monk T, Dennler N, Ralph N, Rastogi S, Afshar S, Urbizagastegui P, Jarvis R, van Schaik A, Adamatzky A
Neural action potentials (APs) are difficult to interpret as signal encoders and/or computational primitives. Their relationships with stimuli and behaviors are obscured by the staggering complexity of nervous systems themselves. We can reduce this complexity by observing that "simpler" neuron-less organisms also transduce stimuli into transient electrical pulses that affect their behaviors. Without a complicated nervous system, APs are often easier to understand as signal/response mec...
Abstract
Cited 8 times since 2024 (7.8 per year)
source: EuropePMC
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin,
Volume 29, Issue 39, 1 1 2024
Increased circulation of GII.17 noroviruses, six European countries and the United States, 2023 to 2024.
Chhabra P, Wong S, Niendorf S, Lederer I, Vennema H, Faber M, Nisavanh A, Jacobsen S, Williams R, Colgan A, Yandle Z, Garvey P, Al-Hello H, Ambert-Balay K, Barclay L, de Graaf M, Celma C, Breuer J, Vinjé J, Douglas A
We report an increase in GII.17 norovirus outbreaks and sporadic infections of acute gastroenteritis in Austria, Germany, France, Ireland, the Netherlands, England and the United States during the 2023/24 season. A decrease in GII.4 coincided with GII.17 prevalence increasing to between 17% and 64% of all GII detections. Overall, 84% of the GII.17 strains clustered closely with strains first reported in Romania in 2021 and two new sub-lineages were identified. Norovirus surveillance and molecula...
Abstract
Cited 9 times since 2024 (8.8 per year)
source: EuropePMC
European heart journal. Cardiovascular Imaging,
Volume 25, Issue 10, 1 1 2024, Pages 1351-1359
Pericoronary adipose tissue for predicting long-term outcomes.
van Rosendael SE, Kamperidis V, Maaniitty T, de Graaf MA, Saraste A, McKay-Goodall GE, Jukema JW, Knuuti J, Bax JJ
Aims: Pericoronary adipose tissue (PCAT) attenuation obtained by coronary computed tomography angiography (CCTA) has been associated with coronary inflammation and outcomes. Whether PCAT attenuation is predictive of major adverse cardiac events (MACE) during long-term follow-up is unknown. Methods and results: Symptomatic patients with coronary artery disease (CAD) who underwent CCTA were included, and clinical outcomes were evaluated. PCAT was measured at all lesions for all three major coronar...
Abstract
Cited 638 times since 2024 (622.5 per year)
source: EuropePMC
European heart journal,
Volume 45, Issue 36, 1 1 2024, Pages 3314-3414
2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).
Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, De Potter TJR, Dwight J, Guasti L, Hanke T, Jaarsma T, Lettino M, Løchen ML, Lumbers RT, Maesen B, Mølgaard I, Rosano GMC, Sanders P, Schnabel RB, Suwalski P, Svennberg E, Tamargo J, Tica O, Traykov V, Tzeis S, Kotecha D, ESC Scientific Document Group
Abstract
Cited 186 times since 2024 (181.5 per year)
source: EuropePMC
European heart journal,
Volume 45, Issue 36, 1 1 2024, Pages 3538-3700
2024 ESC Guidelines for the management of peripheral arterial and aortic diseases.
Mazzolai L, Teixido-Tura G, Lanzi S, Boc V, Bossone E, Brodmann M, Bura-Rivière A, De Backer J, Deglise S, Della Corte A, Heiss C, Kałużna-Oleksy M, Kurpas D, McEniery CM, Mirault T, Pasquet AA, Pitcher A, Schaubroeck HAI, Schlager O, Sirnes PA, Sprynger MG, Stabile E, Steinbach F, Thielmann M, van Kimmenade RRJ, Venermo M, Rodriguez-Palomares JF, ESC Scientific Document Group
Abstract
Cited 660 times since 2024 (644 per year)
source: EuropePMC
European heart journal,
Volume 45, Issue 36, 1 1 2024, Pages 3415-3537
2024 ESC Guidelines for the management of chronic coronary syndromes.
Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, Banning AP, Budaj A, Buechel RR, Chiariello GA, Chieffo A, Christodorescu RM, Deaton C, Doenst T, Jones HW, Kunadian V, Mehilli J, Milojevic M, Piek JJ, Pugliese F, Rubboli A, Semb AG, Senior R, Ten Berg JM, Van Belle E, Van Craenenbroeck EM, Vidal-Perez R, Winther S, ESC Scientific Document Group
Abstract
Cited 1 times since 2024 (1 per year)
source: EuropePMC
Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography,
Volume 37, Issue 12, 1 1 2024, Pages 1188-1190.e3
Right Ventricular to Pulmonary Artery Coupling and Prognosis in Transthyretin Cardiac Amyloidosis.
Meucci MC, Laenens D, Lillo R, Lombardo A, Burzotta F, Stassen J, Debonnaire P, Claeys M, Donal E, Droogmans S, Cosyns B, Jurcut R, Pinto FJ, Brito D, Yedidya I, Van De Heyning C, Sturkenboom N, Graziani F, Ajmone Marsan N
Abstract
Cited 1 times since 2024 (1 per year)
source: EuropePMC
Clinical cancer research : an official journal of the American Association for Cancer Research,
Volume 30, Issue 18, 1 1 2024, Pages 4227-4239
Platinum-Based Chemotherapy Induces Opposing Effects on Immunotherapy Response-Related Spatial and Stromal Biomarkers in the Bladder Cancer Microenvironment.
Chelushkin MA, van Dorp J, van Wilpe S, Seignette IM, Mellema JJ, Alkemade M, Gil-Jimenez A, Peters D, Brugman W, Stockem CF, Hooijberg E, Broeks A, van Rhijn BWG, Mertens LS, van der Heijden AG, Mehra N, van Montfoort ML, Wessels LFA, Vis DJ, van der Heijden MS
Purpose: Platinum-based chemotherapy and immune checkpoint inhibitors are key components of systemic treatment for muscle-invasive and advanced urothelial cancer. The ideal integration of these two treatment modalities remains unclear as clinical trials have led to inconsistent results. Modulation of the tumor-immune microenvironment by chemotherapy is poorly characterized. We aimed to investigate this modulation, focusing on potential clinical implications for immune checkpoint inhibitor respon...
Abstract
Cited 10 times since 2024 (9.7 per year)
source: EuropePMC
The New England journal of medicine,
Volume 392, Issue 5, 31 5 2024, Pages 438-449
Continuation versus Interruption of Oral Anticoagulation during TAVI.
van Ginkel DJ, Bor WL, Aarts HM, Dubois C, De Backer O, Rooijakkers MJP, Rosseel L, Veenstra L, van der Kley F, van Bergeijk KH, Van Mieghem NM, Agostoni P, Voskuil M, Schotborgh CE, IJsselmuiden AJJ, Van Der Heyden JAS, Hermanides RS, Barbato E, Mylotte D, Fabris E, Frambach P, Dujardin K, Ferdinande B, Peper J, Rensing BJWM, Timmers L, Swaans MJ, Brouwer J, Nijenhuis VJ, Overduin DC, Adriaenssens T, Kobari Y, Vriesendorp PA, Montero-Cabezas JM, El Jattari H, Halim J, Van den Branden BJL, Leonora R, Vanderheyden M, Lauterbach M, Wykrzykowska JJ, van 't Hof AWJ, van Royen N, Tijssen JGP, Delewi R, Ten Berg JM, POPular PAUSE TAVI Investigators, POPular PAUSE TAVI Investigators
Background: One third of patients undergoing transcatheter aortic-valve implantation (TAVI) have an indication for oral anticoagulation owing to concomitant diseases. Interruption of oral anticoagulation during TAVI may decrease the risk of bleeding, whereas continuation may decrease the risk of thromboembolism. Methods: We conducted an international, open-label, randomized, noninferiority trial involving patients who were receiving oral anticoagulants and were planning to undergo TAVI. Patients...
Abstract
Cited 10 times since 2024 (9.7 per year)
source: EuropePMC
Nature communications,
Volume 15, Issue 1, 30 5 2024, Pages 7551
Time-series sewage metagenomics distinguishes seasonal, human-derived and environmental microbial communities potentially allowing source-attributed surveillance.
Becsei Á, Fuschi A, Otani S, Kant R, Weinstein I, Alba P, Stéger J, Visontai D, Brinch C, de Graaf M, Schapendonk CME, Battisti A, De Cesare A, Oliveri C, Troja F, Sironen T, Vapalahti O, Pasquali F, Bányai K, Makó M, Pollner P, Merlotti A, Koopmans M, Csabai I, Remondini D, Aarestrup FM, Munk P
Sewage metagenomics has risen to prominence in urban population surveillance of pathogens and antimicrobial resistance (AMR). Unknown species with similarity to known genomes cause database bias in reference-based metagenomics. To improve surveillance, we seek to recover sewage genomes and develop a quantification and correlation workflow for these genomes and AMR over time. We use longitudinal sewage sampling in seven treatment plants from five major European cities to explore the utility of ca...
Abstract
Research and practice in thrombosis and haemostasis,
Volume 8, Issue 6, 30 5 2024, Pages 102558
Erratum to 'Performance of Risk Scores in Predicting Major Bleeding in Left Ventricular Assist Device (LVAD) Recipients: a Comparative External Validation. '[Res Pract Thromb Haemost. 2024;8:e102437].
van der Horst SFB, de Jong Y, van Rein N, Jukema JW, Palmen M, Janssen E, Bonneville EF, Klok FA, Huisman MV, Tops LF, den Exter PL
[This corrects the article DOI: 10.1016/j.rpth.2024.102437.].
Abstract
Cited 3 times since 2024 (2.9 per year)
source: EuropePMC
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions,
Volume 104, Issue 4, 29 5 2024, Pages 655-663
Intravascular lithotripsy in heavily calcified chronic total occlusion: procedural and one-year clinical outcomes.
Oliveri F, van Oort MJH, Al Amri I, Bingen BO, Claessen BE, Dimitriu-Leen AC, Kefer J, Girgis H, Vossenberg T, van der F, Jukema JW, Montero-Cabezas JM
Background: Calcification within chronic total occlusions (CTO) is strongly associated with worse outcomes. Despite the excellent success and safety of intravascular lithotripsy (IVL) in heavily calcified lesions, evidence in CTO remains scarce. Aim: This study aimed to evaluate the procedural and long-term clinical outcomes of IVL in heavily calcified CTO. Methods: Patients who underwent IVL between 2019 and 2024 from an ongoing prospective multicenter registry were eligible for inclusion. Pati...
Abstract
